A detailed history of Russell Investments Group, Ltd. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 406,017 shares of VKTX stock, worth $16 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
406,017
Previous 323,784 25.4%
Holding current value
$16 Million
Previous $17.2 Million 49.76%
% of portfolio
0.04%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $4.1 Million - $5.79 Million
82,233 Added 25.4%
406,017 $25.7 Million
Q2 2024

Aug 08, 2024

SELL
$47.39 - $80.2 $997,132 - $1.69 Million
-21,041 Reduced 6.1%
323,784 $17.2 Million
Q1 2024

May 08, 2024

BUY
$17.4 - $94.5 $1.53 Million - $8.33 Million
88,192 Added 34.37%
344,825 $28.3 Million
Q4 2023

Feb 05, 2024

BUY
$9.24 - $19.64 $2.37 Million - $5.04 Million
256,633 New
256,633 $4.78 Million
Q3 2019

Nov 01, 2019

BUY
$6.55 - $8.6 $126,493 - $166,083
19,312 New
19,312 $133,000
Q2 2019

Aug 09, 2019

SELL
$7.67 - $10.63 $2.39 Million - $3.32 Million
-312,051 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$7.58 - $9.94 $77,785 - $102,004
-10,262 Reduced 3.18%
312,051 $3.09 Million
Q4 2018

Feb 11, 2019

BUY
$7.16 - $16.21 $461,325 - $1.04 Million
64,431 Added 24.98%
322,313 $2.46 Million
Q3 2018

Oct 26, 2018

BUY
$9.7 - $19.65 $1.67 Million - $3.39 Million
172,572 Added 202.29%
257,882 $4.49 Million
Q2 2018

Aug 08, 2018

BUY
$3.88 - $12.74 $293,463 - $963,589
75,635 Added 781.76%
85,310 $810,000
Q1 2018

May 11, 2018

BUY
$4.11 - $6.93 $39,764 - $67,047
9,675 New
9,675 $42,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.01B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.